Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$0.79
-$0.01(-2.91%)
At close: 4:00 PM EDT
$0.79
-$0.01(-2.91%)
Day’s Range― - ―
52-Week Range$0.17 - $5.33
Previous CloseN/A
Volume391.95K
Average Volume (3M)919.18K
Market Cap
$18.55M
Enterprise Value$107.73M
Total Cash (Recent Filing)$19.21M
Total Debt (Recent Filing)$105.85M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding95,417,380
10 Day Avg. Volume2,335,165
30 Day Avg. Volume919,176
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap5.81
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-13.91
Forecast
1Y Price Target
$0.75Price Target Upside-5.06% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$111.12M
Bulls Say, Bears Say
Bulls Say
Revenue ScalingThe substantial multi-year revenue increase shows that MDxHealth has expanded commercial adoption of its molecular testing platform. Continued growth, supported by physician ordering and a broader assay portfolio, can provide a durable foundation for operating leverage and future earnings improvement.
Healthy Gross MarginsGross margins in the roughly 60% to mid-60% range indicate attractive economics for the company’s laboratory testing model. If MDxHealth can sustain these levels while increasing volume, incremental revenue should contribute meaningfully toward covering operating costs and improving profitability.
Clinical And Product DevelopmentPeer-reviewed clinical evidence can strengthen physician confidence and support adoption of MDxHealth’s prostate cancer tests. Ongoing AI initiatives may also extend the usefulness of its platform across customers, creating opportunities for differentiated products and longer-term commercial growth.
Bears Say
Sales Disruption And Guidance SuspensionThe sales-force disruption has already affected quarterly revenue and led management to withdraw its $110–115 million outlook. Continued turnover or slower territory recovery could delay physician adoption, weaken near-term growth, and make the company’s path to sustainable profitability less predictable.
Persistent LossesMDxHealth remains loss-making despite revenue growth, and acquisition-related expenses have increased pressure on operating results. Persistent operating and net losses reduce financial flexibility, require continued cost discipline, and leave the company dependent on successful integration and further revenue expansion.
Balance-Sheet StrainHigher debt, negative equity, and continued negative free cash flow indicate that the business is not yet self-funding. This combination limits flexibility during execution challenges and increases reliance on external financing or improved operating performance to meet obligations and fund growth.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $0.17 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $18.55M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 21 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.013.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Overvalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.09.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 74.892%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$0.75
▼(-5.06% Downside)
Technical Analysis
Ownership Overview
7.23% Insiders
0.10% Mutual Funds
14.27% Other Institutional Investors
78.27% Public Companies and
Individual Investors